Omnicell (OMCL) Competitors

Omnicell logo
$33.18 -1.48 (-4.27%)
Closing price 04:00 PM Eastern
Extended Trading
$33.12 -0.05 (-0.17%)
As of 07:30 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.

OMCL vs. AMN, WST, TFX, HAE, and MMED

Should you buy Omnicell stock or one of its competitors? Omnicell's main competitors and comparable companies include AMN Healthcare Services (AMN), West Pharmaceutical Services (WST), Teleflex (TFX), Haemonetics (HAE), and MiniMed Group (MMED). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "healthcare" sector.

How does Omnicell compare to AMN Healthcare Services?

AMN Healthcare Services (NYSE:AMN) and Omnicell (NASDAQ:OMCL) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, profitability, valuation, media sentiment, earnings, dividends and risk.

Omnicell has a net margin of 3.59% compared to AMN Healthcare Services' net margin of 3.10%. AMN Healthcare Services' return on equity of 23.42% beat Omnicell's return on equity.

Company Net Margins Return on Equity Return on Assets
AMN Healthcare Services3.10% 23.42% 7.19%
Omnicell 3.59%5.69%3.61%

99.2% of AMN Healthcare Services shares are owned by institutional investors. Comparatively, 97.7% of Omnicell shares are owned by institutional investors. 1.1% of AMN Healthcare Services shares are owned by company insiders. Comparatively, 2.9% of Omnicell shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Omnicell has lower revenue, but higher earnings than AMN Healthcare Services. AMN Healthcare Services is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
AMN Healthcare Services$2.73B0.53-$95.70M$2.7513.71
Omnicell$1.18B1.35$2.05M$0.9636.10

In the previous week, AMN Healthcare Services had 6 more articles in the media than Omnicell. MarketBeat recorded 7 mentions for AMN Healthcare Services and 1 mentions for Omnicell. Omnicell's average media sentiment score of 0.84 beat AMN Healthcare Services' score of 0.45 indicating that Omnicell is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
AMN Healthcare Services
2 Very Positive mention(s)
1 Positive mention(s)
4 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omnicell
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

AMN Healthcare Services currently has a consensus price target of $39.17, indicating a potential upside of 3.92%. Omnicell has a consensus price target of $57.86, indicating a potential upside of 66.93%. Given Omnicell's stronger consensus rating and higher probable upside, analysts clearly believe Omnicell is more favorable than AMN Healthcare Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
AMN Healthcare Services
1 Sell rating(s)
4 Hold rating(s)
4 Buy rating(s)
0 Strong Buy rating(s)
2.33
Omnicell
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90

AMN Healthcare Services has a beta of 0.42, meaning that its stock price is 58% less volatile than the broader market. Comparatively, Omnicell has a beta of 0.88, meaning that its stock price is 12% less volatile than the broader market.

Summary

Omnicell beats AMN Healthcare Services on 11 of the 17 factors compared between the two stocks.

How does Omnicell compare to West Pharmaceutical Services?

Omnicell (NASDAQ:OMCL) and West Pharmaceutical Services (NYSE:WST) are both healthcare companies, but which is the superior stock? We will compare the two companies based on the strength of their profitability, risk, analyst recommendations, dividends, media sentiment, earnings, institutional ownership and valuation.

West Pharmaceutical Services has a net margin of 18.81% compared to Omnicell's net margin of 3.59%. West Pharmaceutical Services' return on equity of 21.78% beat Omnicell's return on equity.

Company Net Margins Return on Equity Return on Assets
Omnicell3.59% 5.69% 3.61%
West Pharmaceutical Services 18.81%21.78%15.99%

Omnicell presently has a consensus price target of $57.86, indicating a potential upside of 66.93%. West Pharmaceutical Services has a consensus price target of $424.67, indicating a potential upside of 4.96%. Given Omnicell's higher possible upside, research analysts clearly believe Omnicell is more favorable than West Pharmaceutical Services.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omnicell
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
West Pharmaceutical Services
0 Sell rating(s)
1 Hold rating(s)
13 Buy rating(s)
0 Strong Buy rating(s)
2.93

97.7% of Omnicell shares are owned by institutional investors. Comparatively, 93.9% of West Pharmaceutical Services shares are owned by institutional investors. 2.9% of Omnicell shares are owned by company insiders. Comparatively, 0.6% of West Pharmaceutical Services shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

West Pharmaceutical Services has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than West Pharmaceutical Services, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omnicell$1.18B1.35$2.05M$0.9636.10
West Pharmaceutical Services$3.40B8.30$493.70M$8.9145.41

In the previous week, West Pharmaceutical Services had 5 more articles in the media than Omnicell. MarketBeat recorded 6 mentions for West Pharmaceutical Services and 1 mentions for Omnicell. West Pharmaceutical Services' average media sentiment score of 1.01 beat Omnicell's score of 0.84 indicating that West Pharmaceutical Services is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omnicell
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
West Pharmaceutical Services
3 Very Positive mention(s)
0 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

Omnicell has a beta of 0.88, suggesting that its share price is 12% less volatile than the broader market. Comparatively, West Pharmaceutical Services has a beta of 1.13, suggesting that its share price is 13% more volatile than the broader market.

Summary

West Pharmaceutical Services beats Omnicell on 13 of the 17 factors compared between the two stocks.

How does Omnicell compare to Teleflex?

Omnicell (NASDAQ:OMCL) and Teleflex (NYSE:TFX) are both healthcare companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, institutional ownership, valuation, profitability, analyst recommendations, earnings, media sentiment and risk.

Omnicell has higher earnings, but lower revenue than Teleflex. Teleflex is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omnicell$1.18B1.35$2.05M$0.9636.10
Teleflex$1.99B3.31-$905.64M$8.2320.18

Omnicell presently has a consensus target price of $57.86, suggesting a potential upside of 66.93%. Teleflex has a consensus target price of $163.30, suggesting a potential downside of 1.68%. Given Omnicell's stronger consensus rating and higher probable upside, equities research analysts clearly believe Omnicell is more favorable than Teleflex.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omnicell
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Teleflex
0 Sell rating(s)
6 Hold rating(s)
5 Buy rating(s)
1 Strong Buy rating(s)
2.58

97.7% of Omnicell shares are held by institutional investors. Comparatively, 95.6% of Teleflex shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 0.7% of Teleflex shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Teleflex has a net margin of 13.51% compared to Omnicell's net margin of 3.59%. Teleflex's return on equity of 10.57% beat Omnicell's return on equity.

Company Net Margins Return on Equity Return on Assets
Omnicell3.59% 5.69% 3.61%
Teleflex 13.51%10.57%4.96%

Omnicell has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Teleflex has a beta of 0.85, meaning that its share price is 15% less volatile than the broader market.

In the previous week, Teleflex had 4 more articles in the media than Omnicell. MarketBeat recorded 5 mentions for Teleflex and 1 mentions for Omnicell. Omnicell's average media sentiment score of 0.84 beat Teleflex's score of 0.07 indicating that Omnicell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omnicell
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Teleflex
0 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Summary

Omnicell beats Teleflex on 9 of the 16 factors compared between the two stocks.

How does Omnicell compare to Haemonetics?

Omnicell (NASDAQ:OMCL) and Haemonetics (NYSE:HAE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, institutional ownership, analyst recommendations, dividends, risk, earnings, valuation and media sentiment.

Haemonetics has a net margin of 7.52% compared to Omnicell's net margin of 3.59%. Haemonetics' return on equity of 27.42% beat Omnicell's return on equity.

Company Net Margins Return on Equity Return on Assets
Omnicell3.59% 5.69% 3.61%
Haemonetics 7.52%27.42%9.77%

In the previous week, Haemonetics had 10 more articles in the media than Omnicell. MarketBeat recorded 11 mentions for Haemonetics and 1 mentions for Omnicell. Omnicell's average media sentiment score of 0.84 beat Haemonetics' score of 0.40 indicating that Omnicell is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Omnicell
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Haemonetics
3 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral

Haemonetics has higher revenue and earnings than Omnicell. Omnicell is trading at a lower price-to-earnings ratio than Haemonetics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Omnicell$1.18B1.35$2.05M$0.9636.10
Haemonetics$1.33B4.19$97.31M$2.2355.06

Omnicell currently has a consensus target price of $57.86, indicating a potential upside of 66.93%. Haemonetics has a consensus target price of $130.50, indicating a potential upside of 6.29%. Given Omnicell's stronger consensus rating and higher probable upside, research analysts clearly believe Omnicell is more favorable than Haemonetics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Omnicell
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90
Haemonetics
0 Sell rating(s)
3 Hold rating(s)
9 Buy rating(s)
1 Strong Buy rating(s)
2.85

97.7% of Omnicell shares are held by institutional investors. Comparatively, 99.7% of Haemonetics shares are held by institutional investors. 2.9% of Omnicell shares are held by insiders. Comparatively, 2.1% of Haemonetics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.

Omnicell has a beta of 0.88, meaning that its share price is 12% less volatile than the broader market. Comparatively, Haemonetics has a beta of 0.63, meaning that its share price is 37% less volatile than the broader market.

Summary

Haemonetics beats Omnicell on 11 of the 16 factors compared between the two stocks.

How does Omnicell compare to MiniMed Group?

MiniMed Group (NASDAQ:MMED) and Omnicell (NASDAQ:OMCL) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, risk, media sentiment, analyst recommendations, institutional ownership, dividends, valuation and profitability.

In the previous week, MiniMed Group had 7 more articles in the media than Omnicell. MarketBeat recorded 8 mentions for MiniMed Group and 1 mentions for Omnicell. Omnicell's average media sentiment score of 0.84 beat MiniMed Group's score of 0.45 indicating that Omnicell is being referred to more favorably in the news media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
MiniMed Group
1 Very Positive mention(s)
2 Positive mention(s)
3 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Neutral
Omnicell
0 Very Positive mention(s)
1 Positive mention(s)
0 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive

MiniMed Group currently has a consensus price target of $24.13, suggesting a potential upside of 42.00%. Omnicell has a consensus price target of $57.86, suggesting a potential upside of 66.93%. Given Omnicell's stronger consensus rating and higher possible upside, analysts plainly believe Omnicell is more favorable than MiniMed Group.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
MiniMed Group
1 Sell rating(s)
4 Hold rating(s)
14 Buy rating(s)
0 Strong Buy rating(s)
2.68
Omnicell
0 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
1 Strong Buy rating(s)
2.90

Omnicell has lower revenue, but higher earnings than MiniMed Group. MiniMed Group is trading at a lower price-to-earnings ratio than Omnicell, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
MiniMed Group$3.10B1.54-$333M-$0.68N/A
Omnicell$1.18B1.35$2.05M$0.9636.10

97.7% of Omnicell shares are held by institutional investors. 0.0% of MiniMed Group shares are held by company insiders. Comparatively, 2.9% of Omnicell shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Omnicell has a net margin of 3.59% compared to MiniMed Group's net margin of 0.00%. Omnicell's return on equity of 5.69% beat MiniMed Group's return on equity.

Company Net Margins Return on Equity Return on Assets
MiniMed GroupN/A N/A N/A
Omnicell 3.59%5.69%3.61%

Summary

Omnicell beats MiniMed Group on 11 of the 15 factors compared between the two stocks.

Get Omnicell News Delivered to You Automatically

Sign up to receive the latest news and ratings for OMCL and its competitors with MarketBeat's FREE daily newsletter.

Subscribe Now
SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding OMCL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

OMCL vs. The Competition

MetricOmnicellHealthcare Equipment & Supplies IndustryHealthcare SectorNASDAQ Exchange
Market Cap$1.59B$5.92B$7.59B$11.70B
Dividend YieldN/A1.69%2.48%4.65%
P/E Ratio21.9435.5231.9526.73
Price / Sales1.295.328.415.55
Price / Cash12.5323.4220.7221.66
Price / Book1.164.154.423.65
Net Income$2.05M$143.14M$3.51B$394.00M
7 Day Performance-5.06%-5.25%-6.16%-6.39%
1 Month Performance-7.34%-5.76%-7.05%-8.77%
1 Year Performance-3.91%-1.61%-2.52%-8.48%

Omnicell Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
OMCL
Omnicell
3.6362 of 5 stars
$33.18
-4.3%
$57.86
+74.4%
+0.7%$1.59B$1.18B21.943,580
AMN
AMN Healthcare Services
2.611 of 5 stars
$38.00
+5.0%
$39.17
+3.1%
+136.4%$1.85B$2.73B13.822,664
WST
West Pharmaceutical Services
3.9554 of 5 stars
$413.30
+3.4%
$424.67
+2.7%
+55.6%$28.48B$3.07B46.3910,800
TFX
Teleflex
2.7284 of 5 stars
$155.26
+2.9%
$163.30
+5.2%
+54.4%$6.35B$1.99B17.1315,500
HAE
Haemonetics
2.2118 of 5 stars
$118.12
-1.5%
$126.38
+7.0%
+65.0%$5.80B$1.33B25.433,009

Related Companies and Tools


This page (NASDAQ:OMCL) was last updated on 11/19/2026 by MarketBeat.com Staff.
From Our Partners